Home » Topics » Cardiovascular, BioWorld Science

Cardiovascular, BioWorld Science
RSS

King Saud University discovers new calcium channel blockers

July 25, 2019

Hypertrophic cardiomyopathy model shows potential of phosphomimetic-RLC gene therapy

July 22, 2019

Ambrx announces initiation of phase I study of a long-acting relaxin

July 17, 2019

New hamster model of carotid artery atherothrombotic occlusion developed

July 12, 2019

SP-8356, a CD147 inhibitor, is a potential compound for treating atherosclerosis

July 5, 2019

New phase IIa ELEVATE 1 study investigates RVT-1201 for pulmonary arterial hypertension

July 5, 2019

Low-dose mercury causes heart failure in mice

July 3, 2019

Cerecor announces promising final results from phase I study of CERC-301

July 2, 2019

Phase III study of sildenafil in newborns with PPHN does not meet primary efficacy endpoint

July 1, 2019

Bayer initiates phase II AVANTI study of BAY-1753011 in congestive heart failure

July 1, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...